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Cold-induced urticarial autoinflammatory
syndrome related to factor XII activation
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Hereditary autoinflammatory diseases are caused by gene mutations of the innate immune
pathway, e.g. nucleotide receptor protein 3 (NLRP3). Here, we report a four-generation family
with cold-induced urticarial rash, arthralgia, chills, headache and malaise associated with an
autosomal-dominant inheritance. Genetic studies identify a substitution mutation in gene F12
(T859A, resulting in p.W268R) which encodes coagulation factor XII (FXII). Functional ana-
lysis reveals enhanced autocatalytic cleavage of the mutated protein and spontaneous FXII
activation in patient plasma and in supernatant of transfected HEK293 cells expressing
recombinant W268R-mutated proteins. Furthermore, we observe reduced plasma pre-
kallikrein, cleaved high molecular weight kininogen and elevated plasma bradykinin. Neu-
trophils are identified as a local source of FXII. Interleukin-1β (IL-1β) is upregulated in lesional
skin and mononuclear donor cells exposed to recombinant mutant proteins. Treatment with
icatibant (bradykinin-B2-antagonist) or anakinra (interleukin-1-antagonist) reduces disease
activity in patients. In conclusion, our findings provide a link between contact system acti-
vation and cytokine-mediated inflammation.
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Systemic autoinflammatory diseases (SAIDs) are character-ized by self-directed inflammation that is mediated viaactivation of innate immune pathways. The majority of
SAIDs are rare and disabling disorders with significant morbidity
and quality of life impairment. Within the last 15 years, the
molecular basis of several hereditary SAIDs was uncovered by
using novel high-throughput sequencing techniques. Many of the
affected genes were shown to involve molecules associated with
inflammasome signaling. Inflammasomes are intracellular mul-
tiprotein complexes, which assemble upon recognition of diverse
pathogen- and danger-associated molecular patterns (PAMPs/
DAMPs) leading to activation of caspase-1 to convert pro-inter-
leukin-1β (pro-IL-1β) and pro-IL-18 into their active forms.
Consequently, cytokine-targeted therapies, in particular directed
against IL-1β and its receptor, largely improved the treatment of
SAID patients.
Cryopyrin-associated periodic syndrome (CAPS) is one of the
best-studied hereditary SAIDs. Its hallmark feature is recurrent
urticarial rash combined with systemic symptoms, such as fever
episodes, arthropathy, uveitis, headaches, and malaise. Cold
temperatures represent a major trigger of the disease. CAPS is
caused by a heterozygous mutation in the gene encoding for
nucleotide binding like receptor protein 3 (NLRP3 or cryopyrin)1.
The NLRP3 mutation in CAPS results in an overactivated
inflammasome followed by IL-1β-mediated inflammation. A
diagnosis of CAPS is often delayed, and only eventually made by
excluding other immune-mediated disorders, such as infections,
immunodeficiencies, autoimmune, and neoplastic diseases. Pre-
viously, up to 40% of cases with typical CAPS phenotype were
reported to lack disease-causing NLRP3 mutations, suggesting the
existence of other, as of yet unknown genetic variants2. The
increased use of sequencing techniques identified a number of
somatic CAPS mutations in patients tested negative by conven-
tional Sanger sequencing (depending on the study and phenotype
in 12–69% of individuals)3,4. Besides CAPS, few other genetic
defects were found, including mutations in NLRP12, NLRC4, and
PLCG2. All of them present with early onset urticarial rash
triggered by cold and an autoinflammatory phenotype5–9.
Here, we describe an autosomal-dominant disease character-
ized by cold-induced urticarial rash and systemic inflammation.
The disease is associated with a mutation in the human coagu-
lation Factor 12 gene (F12), and we propose the term FXII-
associated cold autoinflammatory syndrome (FACAS) to denote
this disease. Functional studies show autocatalytic cleavage of
FXII and profound activation of the contact system linked to IL-
1β-mediated inflammation.
Results
Clinical phenotype and disease manifestation. Four family
members of a four-generation family of European ancestry pre-
sented with cold-induced urticarial rash that started within the
first weeks after birth (Table 1; Fig. 1a). The non-pruritic burning
rash occurred on a daily basis at the extremities, face, and trunk,
and was not accompanied by angioedema. Wheal development
typically appeared within 10–30 min after whole-body exposure
to cold temperatures (<15–20 °C) and stayed for one-to-several
hours after rewarming. The urticarial rash was exacerbated by
windy and humid weather. Wheals were induced by sweating and
consecutive evaporative cooling. Direct localized skin contact
with cold fluids or objects, however, did not cause any symptoms.
The skin symptoms associated with signs of systemic inflamma-
tion including chills, joint pain, headache, fatigue, and subfebrile
evening temperatures. All patients had perennial symptoms that
deteriorated during the cold season and frequently lead to
absence from school and work. Over the course of their disease,
patients reported worsening of systemic manifestations, e.g., joint
pain, fatigue, and chills, resulting in a more severe phenotype in
adult patients. The clinical signs were combined with mild-to-
moderate increases in serum levels of the inflammation markers
amyloid A (SAA) and S100 A12/S100 A8/9, but not C-reactive
protein (CRP). Other routine laboratory markers (e.g., liver and
kidney function, blood count, coagulation) were unremarkable.
Histopathology of lesional skin following cold exposure revealed
moderate dermal edema and perivascular infiltrates composed of
macrophages and few neutrophils (Fig. 1b). In contrast to
acquired cold urticaria, affected individuals presented with gen-
eralized urticarial rash upon cold exposure and tested negative in
the ice cube skin provocation test. Cold water bath provocation of
the forearm (15 °C for 10 min) did also not cause any wheals or
angioedema. In addition, all patients reported complete unre-
sponsiveness to oral antihistamines at standard or higher than
standard doses (please see Supplementary Table 1 for a com-
parison of FACAS with other cold-induced urticarial disorders).
A therapeutic trial with IL-1 receptor antagonist anakinra in
patients #1 and #2 resulted only in limited (#2) to moderate
improvement (#1) of clinical symptoms. However, continuous
anti-IL-1 treatment could not be maintained due to severe
injection site reactions.
Genetic analysis. Based on the clinical phenotype resembling
CAPS, Sanger sequencing of NLRP3 and NLRP12 was initially
performed, but failed to identify plausible pathogenic muta-
tions in the index patient (#1). The following whole-exome
sequencing prioritized the assessment of genes that were pre-
viously associated with a skin phenotype of urticaria or urticaria-
like symptoms as reported by the Human Gene Mutation Data-
base (Release 2015.4)10. These were TBXA2R, CEP68, F12,
SERPING1, NLRP3, NLRP12, KIT, IL18, HNMT, FCER1α,
NLRC4, ADGRE2, and PLCG2. Sequencing data were generated
for three affected family members across three generations
(#2, #5, #7, Fig. 1c) and filtered to identify a single candidate
variant, a heterozygous substitution mutation in exon 9 of F12
(Fig. 1d), the gene encoding for the human coagulation factor XII
(NM_000505:c.T859A:p.W268R). The observed variant is not
listed in the Genome Aggregation Consortium (gnomAD) data-
base listing ~140,000 individuals11. In silico predictors of
variant pathogenicity concordantly inferred deleterious impact
(GERP= 5.01; SIFT= 0.0; PolyPhen2= 1.0). Sanger sequencing
of the available family members confirmed consistent segregation
of this mutation with the prior annotation of disease status
(Fig. 1c, d).
FXII exerts diverse functions in coagulation, fibrinolysis,
complement activation, and the kallikrein–kinin system. Muta-
tions in F12 are linked to hereditary angioedema with normal C1
inhibitor (FXII-HAE)12. FXII-HAE is characterized by acute
attacks of localized tissue swellings that are mediated by the
vasoactive peptide bradykinin, which is produced by the plasma
kallikrein–kinin system. Known FXII-HAE mutations are pri-
marily located in the proline-rich region on exon 913,14. In
contrast, the W268R variant lies within the triple-looped kringle
domain of FXII.
Functional analyses. Markers of coagulation (activated partial
thromboplastin time [aPTT], fibrinogen, plasminogen, FXI
activity, D-dimers, INR) and complement activation (C3, C4, C1-
esterase inhibitor [C1-INH] concentration and function) were
normal in all affected family members.
To test, if the FXII-p.W268R substitution in our patients leads
to cleavage and/or activation of FXII associated with contact
system activation and subsequent generation of bradykinin, we
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Table 1 Individual clinical characteristics and manifestations in FACAS patients.
Characteristic Patient ID #1 Patient ID #2 Patient ID #5 Patient ID #7
Age at diagnosis 35 64 9 27
Sex Female Male Female Female
Age at disease onset After birth After birth After birth After birth
Skin symptoms Cold-induced urticarial rash Cold-induced urticarial rash Cold-induced
urticarial rash
Cold-induced
urticarial rash
CNS symptoms Headache Headache Headache Headache
Musculo-skeletal symptoms Moderate arthralgia Severe arthralgia None Mild arthralgia
Systemic symptoms Fatigue, subfebrile
temperatures
Fatigue, subfebrile
temperatures
Fatigue Fatigue
S100 A12 in ng/ml (ref. <200) 523.7 n.a. 1024.3 n.a.
S100 A8/9 in µg/ml
(ref. <2.94)
n.a. 4.10 n.a. 4.51
Serum amyloid A in mg/l
(ref. <6.40)
16.80 n.a. n.a. 8.20
a
c.T859A (W268R)
Wild type
#3
#7#1
#6#5
#4
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Fig. 1 Phenotype and genotype in patients with FXII-associated cold autoinflammatory syndrome (FACAS). a Urticarial rash of the face of a 9-year-old
girl and the leg of her 35-year-old mother. b Skin histopathology reveals dermal edema (H.E. yellow arrow) and perivascular infiltrates composed of
macrophages (CD163) and few intravascular neutrophils (myeloperoxidase [MPO], yellow arrow). Original magnification ×400 (n= 2 technical
replicates). c Family pedigree over four generations identifying affected (shaded black) and unaffected (unshaded) individuals. Exome sequenced
individuals are underlined. Where conducted, the results of Sanger sequencing of p.W286R are shown to top left of each individual whereby “+” denotes
heterozygote for variant and wild-type, and “−” denotes healthy reference. d Representative sequencing chromatogram of the heterozygous genotype in an
affected individual (top) and chromatogram of healthy individual from the same region (bottom).
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first assessed FXII fragmentation and activity. For its activation,
FXII needs to be cleaved into a two-chain molecule composed of
a heavy- and a light-chain linked by a disulfide bond15. In
addition to the unprocessed FXII (78 kDa), molecular analyses
revealed an increased presence of the 50 kDa band (reducing) in
the FXII immunoblot from plasma of affected family members,
which was hardly detectable in healthy control family members
and an FXII-HAE control (Fig. 2a). This band resembled the
heavy chain of active FXII (FXIIa), suggesting partial fragmenta-
tion and activation of FXII in affected patients. Accordingly,
recombinant FXII-p.W268R (rFXII W268R) expressed in
HEK293 cells also showed the characteristic 50 kDa (III) band
in the FXII immunoblot resembling the heavy chain. This band is
also present in purified αFXIIa, but not found in unprocessed
recombinant FXII (rFXII wt) (Fig. 2b). In addition to the heavy
chain, the light chain at 25 kDa (IV) was found in preparations of
αFXIIa and rFXII W268R, but not in rFXII wt. Treatment of
rFXII W268R with kaolin resulted in increased generation of the
light-chain fragment. Besides the heavy and light chains at 50 kDa
and 25 kDa, respectively, we found in the rFXII W268R
preparation a third fragment with an apparent molecular weight
of 60 kDa (reducing) that was absent in the αFXIIa preparation
(Fig. 2a, b). Mass spectrometry analysis of excised gel fragments
confirmed the autoproteolytic cleavage of rFXII W268R at
residues AA353/354, which yields in FXIIa. In addition, analysis
of the 60- kDa fragment revealed cleavage of rFXII W268R after
AA447, which is part of the protease domain and facilitated by
kaolin treatment (Fig. 2c). In line with these observations which
suggest autoactivation of FXII W268R, we found high sponta-
neous activity of FXIIa in the plasma of affected family members
(Fig. 2d) as well as in the supernatant of FXII W268R-expressing
HEK293 cells, but not in the plasma of healthy family members
or wt-FXII expressing HEK293 cells (Fig. 2d, e). Interestingly,
overall plasma levels of FXII were comparable with healthy
controls (Supplementary Fig. 1), indicating that the p.W268R
mutation only affects the probability of spontaneous FXII
activation, but not its expression.
We next assessed mediators of the kallikrein–kinin pathway.
High FXIIa activity was associated with pronounced plasma
prekallikrein (PK) cleavage and kallikrein formation (Fig. 3a)
similar to what is found in activated recombinant PK prepara-
tions (Supplementary Fig. 2). In line with these findings, we
noticed reduced PK activity and plasma levels in affected patients
(Fig. 3b, c). FXII-mediated contact system activation is counter-
balanced by C1-INH to prevent continuous kallikrein and
bradykinin formation. Thus, our observation of increased
FXIIa-C1-INH and PK-C1-INH complexes in FACAS plasma
reflected an imbalanced and constitutively active contact system
(Fig. 3d, e). Kallikrein cleaves high-molecular-weight kininogen
(HMWK) to release bradykinin, a potent but short-lived
vasoactive mediator acting on bradykinin B2 receptors. Since
bradykinin becomes rapidly degraded by kininases16, cleaved
HMWK (cHMWK) is used as a surrogate marker of plasma
bradykinin formation17. Interestingly, we found complete degra-
dation of HMWK in the immunoblot of all tested FACAS
patients (Fig. 3f). Correspondingly, the activity of cHMWK was
clearly upregulated in patients vs. controls (Fig. 3g). Of interest,
bradykinin plasma levels which were available from two FACAS
patients revealed higher values compared with healthy controls
(Fig. 3h).
To investigate the possibility of local FXII production and
activation at sites of inflammation, we evaluated the lesional skin
of a FACAS patient following cold exposure. Immunohistochem-
istry revealed FXII expression by intra- and perivascular
neutrophils (but not macrophages; Supplementary Fig. 3) as
demonstrated by cytoplasmatic co-staining with antibodies for
myeloperoxidase (MPO) and α-FXIIa heavy chain (Fig. 4a).
Moreover, we found FXII expression in single peripheral blood
neutrophils purified from an affected patient, but not in healthy
controls (Fig. 4b). Together, these findings could point toward
local FXII production by neutrophils in the skin of FACAS
patients. As monocytes and tissue macrophages are known to
recruit neutrophils via IL-8 secretion18,19, we hypothesized that
contact system mediators might induce the attraction of
neutrophils. Accordingly, we found dose-dependent IL-8 release
from monocytes treated with increasing doses of bradykinin
(Fig. 4c).
FXIIa and bradykinin were previously shown to induce IL-1β
secretion from human monocytes and macrophages20,21. Assum-
ing that FXIIa and/or consecutive mediators like bradykinin affect
the IL-1β-related phenotype in FACAS, we investigated IL-1β
responses in patient samples. Basal IL-1β secretion from patient
PBMCs was negligible and comparable with healthy control
PBMCs (Supplementary Fig. 4). However, exposure of healthy
donor PBMCs to recombinant FXII proteins (wild-type and
W268R) suggested an IL-1β priming effect of the FXII W268R
mutant protein but not wild-type protein when co-stimulated
with the NLRP3 activator ATP (without LPS) (Fig. 5a). To
investigate whether the IL-1β priming effect was mediated via
FXIIa activity, we assessed the potential of recombinant FXII
W268R with an S544A inhibitory mutation22 (rFXII W268R-
S544A) and αFXIIa to induce IL-1β release in PBMCs. Moreover,
we blocked protease activity with the small peptide-based
inhibitor PPACK (Phe-Pro-Arg-chloro-methylketone). Remark-
ably, the incapacitated S544A mutant protein showed a similar
IL-1β priming effect as the active rFXII W268R (Fig. 5b). In
contrast, the priming effect on IL-1β synthesis was absent in
PBMCs treated with αFXIIa (Fig. 5c). Also, in LPS-primed and
ATP-activated PBMCs, addition of FXIIa or FXIIa-PPACK did
not induce significant changes on IL-1β release (Fig. 5c).
Together, these results demonstrate that the priming effect on
IL-1β synthesis is not linked to FXIIa activity.
When analyzing biopsies from lesional FACAS skin, we
observed pronounced IL-1β expression (Fig. 5d, e). Positive IL-
1β staining co-localized with perivascular neutrophils and
macrophages, suggesting these cells as the primary source for
IL-1β in the skin.
Clinical efficacy of bradykinin B2 receptor antagonism. Based
on the collected evidence for excessive contact system activation
in FACAS, we initiated a short treatment course over 4 con-
secutive days with the bradykinin B2 receptor antagonist icatibant
in the index patient (patient #1). Individual symptoms were
assessed by a patient-reported standardized daily health assess-
ment form that was adapted from a validated tool for CAPS23.
Within 30 min after the first administration of 30 mg icatibant,
the generalized urticarial rash and systemic symptoms improved.
The maximum effect (absence of rash and headache, largely
improved fatigue) occurred after 90 min and lasted for up to 12 h.
Icatibant treatment was initiated during the winter and tolerated
well. It completely abrogated skin and systemic symptoms while
staying outside for several hours at temperatures below 0 °C. Only
arthralgia was still mildly present. Complete relapse of symptoms
occurred within 24 h after drug withdrawal (Fig. 6).
Discussion
We report a dominantly inherited cold-induced urticarial auto-
inflammatory disease in a four-generation family that is asso-
ciated with a c.T859A mutation in F12 leading to an amino acid
exchange of tryptophan by an arginine (p.W268R). Functional
analyses of the mutant protein revealed high susceptibility to
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Fig. 2 FXII W268R results in fragmentation and spontaneous activation of FXII. a FXII fragmentation in FACAS plasma samples and FXII W268R mutant
proteins. Citrate plasma of affected (#1, #2, #5) and non-affected (#3, #4, #6) family members, recombinant wild-type and W268R FXII expressed in
HEK293 cells and plasma from an FXII-HAE patient was separated by SDS-PAGE (reducing blot) and immunoblotted for FXII. Red arrows at 50 kDa
indicate heavy chain of cleaved FXII in the plasma of affected patients and recombinant W268R FXII (rFXII W268R), which is barely visible in non-affected
and hereditary angioedema (HAE) III plasma or wild-type FXII (rFXII wt). Recombinant W268R and wild-type FXII were expressed in HEK293 cells. Black
arrows point to rFXII W268R fragments observed by mass spectrometry in c, n= 5 technical replicates. b Immunoblot (reduced conditions) of recombinant
mutant proteins (in the presence or absence of surface activator kaolin) and controls (rFXII wt and purified αFXIIa). In addition to 50 kDa (heavy chain, HC)
and 25 kDa (light chain, LC) bands, a further band appears at 60 kDa (II) that is absent in rFXII wt and αFXIIa. Black arrows point to rFXII W268R fragments
observed by mass spectrometry in c, n= 3 technical replicates. c Schematic presentation of FXII W268R procession. Red arrows point to mutation at
position W268R. Proteolytic sites are indicated by blue arrows. Cleavage after position 353 results in FXIIa W268R HC (50 kDa) and FXIIa W268R LC
(25 kDa) fragments. Additional cleavage results in a truncated FXII W268R fragment (60 kDa) cleaved at position 447. d FXIIa activity was measured by a
chromogenic assay demonstrating considerable spontaneous FXIIa activity in plasma of affected individuals (n= 3), but less in healthy donors (n= 3
healthy family members). e Spontaneous FXIIa activity was also observed in culture supernatants from HEK293 cells expressing W268R, but not wild-type
FXII. Graphs show individual data points and the mean ± s.e.m. Statistical significance is indicated by unpaired Student’s t test with Welch’s correction
(d, e). Source data are provided as a source data file.
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autocatalytic cleavage after residue AA353, which is known to be
associated with FXIIa formation. This is paralleled by constitutive
activation of the p.W268R variant of FXII resulting in an over-
active contact system and release of potent inflammatory cyto-
kines such as IL-1β. The relevance of bradykinin as a critical
mediator is underlined by the immediate clinical response to
treatment with the bradykinin B2 receptor antagonist icatibant.
Skin and systemic symptoms associated with IL-1β-mediated
inflammation in FACAS are reminiscent of the clinical phenotype
of CAPS. Its underlying mechanisms, however, are different and
share signaling cascades of kallikrein–kinin activation with HAE.
FXII is primarily produced and secreted by hepatocytes. It
circulates as a single-chain inactive zymogen in the plasma and
converts into FXIIa (composed of an N-terminal heavy chain and
a C-terminal light chain) upon contact with negatively charged
surfaces such as polyphosphates released by platelets or by limited
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Fig. 3 FXII W268R activates the kallikrein–kinin pathway. a Citrate plasma of affected (n= 3) and healthy family members (n= 3) was immunoblotted
for prekallikrein (PK) showing substantial cleavage of PK (black arrow) to kallikrein (red arrow), n= 2 technical replicates. This corresponds to reduced PK
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proteolysis15. In the pathogenesis of FXII-HAE, defective glyco-
sylation augments contact-mediated FXII autoactivation, which
enhances bradykinin formation via the kallikrein–kinin system24.
Our data, showing partially cleaved and active FXII in patient
plasma as well as enzymatic activity of recombinant W268R in
cell culture supernatants, suggest spontaneous, intracellular con-
version of FXII into FXIIa in FACAS. In contrast, spontaneous
FXII cleavage was absent in FXII-HAE plasma, which is in line
with previous reports showing the need for a plasmatic trigger to
cleave and activate FXII in HAE25.
The novel mutation induces an exchange of tryptophan to
arginine (W268R) inside the kringle domain of FXII. Kringles are
common in members of the coagulation cascade and are thought
to play essential roles in binding target molecules/structures, such
as membranes, other proteins, or phospholipids, and in the reg-
ulation of proteolytic activity26,27. Our observation of fragmented
rFXII-W268R that is cleaved after residue AA353 argues for
increased autoactivation and may explain the high spontaneous
FXIIa activity observed in plasma and supernatant of HEK293
cells transfected with rFXII-W268R. These findings differ from
recent studies in FXII-HAE with p.T309R mutation. This variant
was demonstrated to be enzymatically truncated after residue
AA309 resulting in the loss of the heavy-chain fragment and
dysregulated PK activation28. Our data do not support truncation
of W268R after residue AA268. In contrast, we observed addi-
tional cleavage after AA447 in the recombinant protein. However,
this was not detected in plasma of the affected patients, suggesting
that this might be the result of artificial expression in HEK293
cells. From our data, we conclude that high susceptibility to
cleavage at the regular cleavage site at AA353/354 leads to con-
tinuously increased FXIIa activity. In addition, the exchange of
the aromatic and lipophilic tryptophan to the hydrophilic and, at
physiological pH, positively charged arginine may foster binding
of mutant FXII to negatively charged surfaces, thereby further
enhancing its activation state leading to an exhaustion of the
contact system with fully cleaved PK and HMWK, and constantly
raised bradykinin levels in the patient plasma.
Neutrophil-dominated dermal infiltrates are known from
urticarial autoinflammatory diseases Schnitzler’s syndrome and
CAPS29. These are classified as neutrophilic urticarial dermatosis
as opposed to the rather sparse lympho-histiocytic infiltrates in
lesional skin of common urticaria. Their role, however, remains
ill-defined. Interestingly, peripheral blood neutrophils were pre-
viously shown to produce zymogen FXII, which functionally
differs from hepatic FXII and contributes to neutrophil trafficking
via cell adhesion, migration, and release of extracellular DNA at
sites of inflammation30. Conceivably, the generalized urticarial
rash in FACAS could be mediated via neutrophil-derived and
pre-activated FXII at the sites of inflammation as suggested by the
cytoplasmatic expression of αFXIIa in the skin and peripheral
blood neutrophils. IL-8 is known to induce neutrophil recruit-
ment19. Supported by our data, plasma-derived BK may induce
IL-8 production by skin macrophages to recruit neutrophils
(Fig. 7). We hypothesize that upregulated FXII expression in
FACAS neutrophils may be mediated via a paracrine feedback
loop involving contact system components such as plasma kal-
likrein and HMWK. These were both shown to activate (and in
Fig. 4 FXII is expressed by skin and blood neutrophils in FACAS.
a Representative image from serial sections of the lesional skin of FACAS
patient ca. 1 h after cold exposure. FXII immunoreactivity is restricted to
neutrophils at perivascular sites and within blood vessels (white arrows),
n= 2 technical replicates. b Exemplary images from cytospins isolated from
the peripheral blood of FACAS patients and healthy control subjects. Only
single FACAS neutrophils (0.72%), but not healthy control neutrophils
(0%), present with double-positive cytoplasmatic staining for FXII and
MPO. Original magnification ×400, n= 3 technical replicates. c Peripheral
blood mononuclear cells were isolated from healthy control subjects by
density-gradient centrifugation and stimulated with increasing doses of
bradykinin. IL-8 secretion was assessed by ELISA. Pooled data of n= 3
different donors, n= 2 technical replicates. The graph shows individual data
points and the mean ± s.e.m. Statistical significance is indicated by one-way
ANOVA with Sidak’s multiple comparisons. Source data are provided as a
source data file.
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Fig. 5 FXII W268R induces and increases IL-1β secretion and expression. a–c Peripheral blood mononuclear cells were isolated from healthy control
subjects by density-gradient centrifugation. Interleukin-1β (IL-1β) secretion requires a two-step process: (i) transcriptional upregulation of pro-IL-1β via toll-
like receptors and (ii) conversion of pro-IL-1β into its active form by inflammasome activation. Cells were pre-stimulated with toll-like receptor agonist
lipopolysaccharide (LPS), and nucleotide binding like receptor protein 3 (NLRP3) inflammasome activation was induced by the danger molecule ATP (LPS+
ATP= blue symbols). Red symbols denote LPS-stimulated cells only, and green symbols represent ATP-activated cells without priming by LPS.
Experiments were performed in the presence of FXII-depleted plasma (control) and addition of recombinant FXII wild-type (rFXII wt) and W268R (rFXII
W268R) protein (a) or rFXII W268R-S544A (b). Experiments in (c) were conducted with purified FXII, FXIIa, and different doses of the small peptide-
based inhibitor PPACK. Black arrows indicate priming effect by the mutant rFXII W268R (a) and the active site incapacitated rFXII W268R-S544A (b),
which was absent in rFXII wt and control. Also, the presence of FXIIa (with or without PPACK) did not induce changes in IL-1β release (c). IL-1β secretion
was assessed by ELISA. Pooled data of n= 3 different (a) or n= 2 (b, c) experiments. Bar graphs show individual data points and the mean ± s.e.m.
Statistical significance in is indicated by one-way ANOVA (a, c) with Tukey’s multiple comparisons test for ATP between the groups control vs. rFXII
W268R and rFXII wt vs. rFXII W268R (a) or unpaired Student’s t test (b). d, e Representative image from serial sections of the lesional skin from FACAS
patient following cold exposure exhibits IL-1β immunoreactivity. IL-1β expression is pronounced around blood vessels (yellow arrows) and co-localizes with
neutrophils (d) and macrophages (e) (white arrows). Original magnification ×400, n= 2 technical replicates. Source data are provided as a source
data file.
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case of HMWK also bind to) neutrophils31,32. Thus, the high
degree of contact system activation could be the reason why FXII
expression was restricted to FACAS and not observed in healthy
control neutrophils.
The sensitivity to cold as a trigger and amplifier of clinical
symptoms in FACAS is known from autoinflammatory diseases
such as CAPS. Here, cold was proposed to escalate constitutive
inflammasome activity via increased production of reactive oxy-
gen species induced by cellular stress to temperature shifts33. In
FACAS, however, inflammasomes of mononuclear cells are not
constitutively activated (Supplementary Fig. 4), suggesting alter-
native mechanisms. Of interest, C1-INH activity was previously
reported to be inhibited by cold as shown by complete plasma
HMWK cleavage at 0 °C in vitro34. We assume that cold-induced
decreases in tissue C1-INH activity may contribute to an imbal-
anced contact system in FACAS. Temperatures above a certain
threshold (clinically around 20 °C) may protect from
inflammatory symptoms because of adequate local C1-INH
activity that counterbalances kallikrein activation. Based on this
hypothesis, lower temperatures will reduce C1-INH activity
leading to spontaneous but locally restricted activation of the
kallikrein-kinin pathway and bradykinin production in the tissue,
sufficient for wheal induction but not angioedema.
Bradykinin drives the inflammation in experimental models of
osteoarthritis and neuroinflammation via upregulation of cyto-
kines such as IL-1β35,36. Vice versa, IL-1β is known to augment
the accumulation of bradykinin via upregulation of bradykinin
receptors37,38 and activation of prekallikrein–HMWK com-
plexes39. Also, IL-1β downregulates angiotensin-converting
enzyme (ACE) expression in endothelial cells, resulting in less
efficient bradykinin elimination40. Accordingly, elevated skin and
systemic IL-1β levels in FACAS may amplify inflammatory
responses via a positive feedback loop that induces further bra-
dykinin production. Moreover, bradykinin was shown to activate
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Fig. 6 The bradykinin B2 receptor antagonist icatibant resolves FACAS signs and symptoms. During winter with continuous skin symptoms, the index
patient administered icatibant 30mg. a Urticarial rash completely resolved within 90min post icatibant application (from the left to right). b Total and
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the main symptoms rash, fatigue, headache, arthralgia, and fever/chills. The total score ranges from 0= no symptoms to 50=maximum of symptoms.
Each subscore can range from 0= no symptoms to 10=maximum of symptoms. The subscores do not show fever/chills as these symptoms were not
present at that time. Icatibant was given on 4 consecutive days (red arrows).
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and degranulate mast cells in vitro resulting in the release of
heparin and polyphosphates, which may facilitate the local pro-
duction of bradykinin via FXII activation41,42. Also, skin mast
cells contribute to IL-1β-mediated inflammation in urticarial
autoinflammatory diseases43, and their abundant expression and
activation may promote the urticarial phenotype in FACAS
patients (Fig. 7).
The clinical response to treatment with the IL-1 receptor
antagonist anakinra mirrors the increased presence of IL-1β in
FACAS tissue similar to other urticarial autoinflammatory dis-
eases such as CAPS. Incomplete clinical improvement by ana-
kinra may be explained by continuous bradykinin generation via
complex feedback loops and possibly further cytokines such as
TNFα, which are induced by bradykinin44 and not inhibited by
IL-1 blockade. Of further interest, our findings suggest that the
p.W268R variant can prime cells for IL-1β production via
pattern-recognition receptors, without the need of an exogenous
stimulus by pathogen-associated molecular patterns such as LPS.
Surprisingly, the IL-1β priming effect is not linked to FXIIa
activity as shown by the missing impact of αFXIIa on IL-1β
secretion. Thus, we believe that conformational changes of FXII p.
W268R result in the recognition as a danger signal that serves as
toll-like receptor agonist and inducer of IL-1β release.
The prompt and striking clinical response to the bradykinin B2
receptor antagonist icatibant is in line with its efficacy in HAE
patients and strongly supports our model of a bradykinin-
mediated mechanism. Reasons for the persistence of mild
arthralgia may be the short treatment duration of icatibant or the
fact that bradykinin effects on joint inflammation are mediated
via the B1 receptor rather than the B235.
Limitations of our study include the small patient and sample
sizes. Until now, there are no other families or individuals known
with FACAS. Hence, it will be important to screen patients with
similar phenotypes for the FXII p.W268R mutation in order to
confirm our data. The mechanism by which cold induces
inflammation as well as the role of neutrophils in FACAS need to
be further evaluated. Also, the duration of treatment with ana-
kinra and icatibant was only short due to side effects and limited
efficacy (anakinra) or limited availability (icatibant). Data on
long-term efficacy are still missing.
In conclusion, the pathomechanisms underlying this novel
disease illustrate the critical role of fragmented and pre-activated
FXII in driving skin and systemic inflammation as well as the
close link between contact system activation and cytokine sig-
naling. Therapeutic approaches in FACAS should aim at con-
tinuous control of inflammation in order to prevent long-term
sequelae such as amyloidosis. Based on the short half-life of
icatibant of few hours, inhibitors of contact activation including
kallikrein antagonists and FXII antibodies are promising drug
candidates of interest.
Methods
Patients. A total of eight family members, four of them affected and four non-
affected, were analyzed. All of them provided written informed consent. This
included the publication of individual data. For affected children, parents provided
written informed consent, respectively. The authors affirm that human research
participants provided informed consent for publication of the images in Figs. 1a,
6a. The study was approved by the local Charité Ethics Committee, Charité—
Universitätsmedizin Berlin, Germany.
Genetic studies. Genomic DNA was isolated from saliva samples of eight family
members, and whole-exome sequencing (SureSelect human all exon v5.0, Agilent,
Santa Clara, California) of three affected family members across three generations
was performed and analyzed as described before in greater detail45. Briefly, genetic
variants in the candidate genes were filtered to be present in all three sequenced
individuals (in any zygosity) and to occur at <5% in 1000 Genomes database. DNA
was available for follow-up Sanger sequencing from seven family members
including all four affected individuals to determine consistency of variant segre-
gation with disease. DNA exome capture was performed using the SureSelect
human all exon v5 kit according to the manufacturer’s protocol and the library
sequenced on the HiSeq 2000 platform (Illumina, San Diego, California), gen-
erating data sufficient to provide > 50× coverage across the exome. Read data were
aligned using Novoalign v2.08 and duplicate reads marked using Picard v1.97.
Variant calling was performed using Samtools v0.1.19 and variants annotated using
Annovar (23rd August 2013 release) utilizing RefSeq gene definitions. Candidate
genes were identified in HGMD release 2015.4 using the search term urticaria.
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Fig. 7 Proposed pathomechanism underlying FXII W268R mutation in FACAS. Liver-derived and pre-activated FXII induces plasma prekallikrein cleavage,
HMWK cleavage leading to constantly raised bradykinin (BK) levels in the patient plasma (1) and increased permeability of the vasculature (3). BK may
also induce IL-1β release from monocytes and tissue macrophages (Mɸ) leading to the autoinflammatory phenotype observed in FACAS patients (2), (5).
IL-1β may further induce BK accumulation by upregulation of its receptors and downregulation of its inactivating enzyme ACE (4). In the skin, BK activates
Mɸ to produce IL-8 and IL-1β, recruiting neutrophils into the tissue (5). These neutrophils may act as a source of auto-activated FXIIa in the skin, which
leads to further contact system activation and BK generation (6). Under normal conditions, C1-Inhibitor can control BK generation, however, upon cold
exposure inhibitory capacity may drop leading to a local increase in BK. Activation of neutrophils may occur via a paracrine feedback loop involving plasma
kallikrein and HMWK. In addition, BK may activate skin mast cells to release heparin and polyphosphates (7), which supports further activation of FXII.
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Segregation analysis was performed on amplicons generated using primers for-
wards 5′-CTAACCTCCCGGGGTCTG-3′ and reverse 5′-CAGACCCCGGGAGG
TTAG-3′ using standard techniques. Unidirectional Sanger sequencing was per-
formed using the forward primer.
Blood collection. Following standard procedures, nine volumes of blood were
collected in one volume of sodium citrate, (3.2% w/v). Samples were centrifuged
twice at 2000×g for 10 min. Plasma from FACAS-affected family members and
from healthy donors was stored in aliquots at −80 °C until use. For PBMC sti-
mulation assays, blood from FACAS-affected family members or healthy control
donors was sampled into lithium heparin tubes and processed as explained below.
Citrate and heparin tubes were from Greiner Bio One (Kremsmünster, Austria).
For plasma bradykinin level assessment, blood was sampled into SCAT-169-4.5/5
protease inhibitor blood collection tubes (Haematologic Technologies, Essex
Junction, Vermont), centrifuged at 2000 × g for 10 min and stored as
described above.
Western blot. Frozen plasma of affected and healthy individuals was thawed on
ice, diluted 1:10 (FXII), 1:20 (HMWK), or 1:40 (PK) in sample buffer (15.5%
glycerol, 96.8 mM Tris-HCl, 3.1% SDS, and 0.003% bromophenol blue, 25 mM
DTT (Sigma-Aldrich, St. Louis, Missouri)), boiled for 5–10 min and briefly chilled
on ice. Recombinant constructs were treated similarly. Approximately 50–100 ng
total protein of recombinant proteins or 5 µl of plasma sample were loaded and
separated on 10% Tris/glycine or Bolt 4–12% Bis-Tris Plus Gels (Merck-Millipore)
and separated at 200 V (running buffer 190 mM glycine, 25 mM Tris, 0.1% SDS) or
165 V (MOPS running buffer (Merck-Millipore, Amsterdam, The Netherlands)),
respectively, for 1 h. The gels were washed for 5 min in blotting buffer (14.4 g/l
glycine, 3.03 g/l, Tris-HCl, 20% ethanol) and Whatman Protran nitrocellulose
membranes (BA85, pore size 0.45 µm (Sigma-Aldrich)) were activated in blotting
buffer for 5 min as well. Proteins were transferred onto nitrocellulose membranes
with the TransBlot Turbo (BIORAD, Hercules, CA) for 30 min at 25 V and 1 A in
190 mM glycin, 25 mM Tris, 15% methanol or onto Immobilon-FL membranes
(Merck-Millipore) at 125 V for 55 min in blotting buffer. The membranes were
blocked for 1 h using Odyssey Blocking Buffer (LI-COR, Hamburg, Germany)
diluted 1:1 with Tris-buffered saline (TBS; 50 mM Tris-HCl and 150 mM NaCl, pH
7.4). PK, HMWK and FXII were detected with affinity-purified polyclonal anti-
bodies at 1:4000 (CL20090A, CL20027AP and CL20055AP, respectively, Cedarlane,
Burlington, Canada) by overnight incubation at 4 °C. Membranes were washed
with TBS, 0.05% Tween-20, and probed with Donkey-anti-goat-IgG DyLight800
conjugate (C30530-01, LI-COR) at 1:40,000 or Alexa Fluor 680 donkey anti-sheep
IgG 1:5000 (A-21102, Thermo Fisher Scientific, Waltham, MA) for 1 h at room
temperature. Membranes were washed again with TBS, 0.05% Tween-20, and
images were developed using the Fusion FX (Vilber Lourmat, Eberhardzell, Ger-
many) or a near-infrared Odyssey scanner (LI-COR) with excitation/emission at
640 nm/680 nm or 740 nm/800 nm.
Mass spectrometry. FXII proteins (WT and W268R, full-length and cleavage
products) planned to be analyzed by mass spectrometry were applied to 10% SDS-
PAGE as described above (1 µg/lane), stained overnight at 4 °C using Instant Blue
(ISB1L, Expedeon San Diego, California) and destained for ≥1 h at ambient with
destaining solution (10% acetic acid, 20% ethanol). Defined bands were cut by
scalpel, and sent for mass spectrometry at BIH Proteomics (Max Delbrück Center,
D-13125 Berlin). Tryptic digest was performed in-gel on defined bands (Fig. 2b I,
II, III, IV). Each band was cut into small pieces, washed with 50 mM ABC
(ammonium bicarbonate) and 50% ethanol/50 mM ABC buffer, dehydrated with
100% Ethanol and vacuum dried, incubated for 45 min with 10 mM DTT at 56 °C,
followed by 45 min incubation with 55 mM chloroacetamide (Merck-Millipore).
After one round of 50 mM ABC and 50% ethanol/50 mM ABC buffer wash, gel
pieces were dehydrated with 100% ethanol, dried and each sample was incubated
with 1 µg trypsin (sequence-grade modified, V5111, Promega, Madison, Wiscon-
sin) in 50 mM ABC buffer overnight at 37 °C. After acidifying, the samples with
formic acid (2% final concentration), peptides were extracted with 30% ethanol/
50 mM ABC followed by 100% acetonitrile. The supernatants were combined and
dried down. The resulting peptide pellet was dissolved in 3% acetonitrile/0.1%
formic acid and analyzed by mass spectrometry. For mass spectrometric mea-
surements, the peptide mixture was separated by reversed-phase chromatography
using an EasyLC 1200 system (Thermo Fisher Scientific) on in-house-
manufactured 20-cm fritless silica microcolumns packed with ReproSil C18 resin
(inner diameter 75 µm, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany).
Peptides were separated using an 8–60% acetonitrile gradient (44 min length) at a
nanoflow rate of 250 nl/min. Eluting peptides were directly ionized by electrospray
ionization and analyzed on a Q Exactive HF-X (Thermo Fisher Scientific). Mass
spectrometry was performed in data-dependent positive mode with one full scan
(m/z range= 350–1800; R= 60000; target value: 3 × 106; maximum injection
time= 45 ms). The Top 20 most intense ions with a charge state between 2 and 7
were selected (R= 45000, target value= 1 × 105; isolation window= 1.3 m/z;
maximum injection time= 86 ms). Dynamic exclusion for selected precursor ions
was set to 20 s. Data analysis was performed using MaxQuant software package
(version 1.6.0.146). The internal Andromeda search engine was used to search MS2
spectra against human coagulation factor XII wild-type and W268R mutant
sequence containing forward and reverse sequences. A database for contaminants
was included. The search included variable modifications of methionine oxidation,
N-terminal acetylation, deamidation (N and Q), and the fixed modification of
carbamidomethyl cysteine. Minimal peptide length was set to six amino acids,
digestion parameter was semitryptic. The FDR was set to 0.01 for peptide, protein,
and site identifications. To filter for confidently identified peptides, a minimum of
two MS counts and valid value in both replicates for at least one sample group were
required. Intensity values were log2 transformed. Mass spectrometry was per-
formed twice; n= 2 duplicates were assessed for each band.
Factor XII protein expression and purification. The eukaryotic expression vector
pcDNA6/V5-His A (Thermo Fisher Scientific) was modified by insertion of a
murine Igκ secretion signal and two strep-tags through the HindIII and EcoRI
digestion sites (called pSM2). cDNA of the F12 gene was kindly donated by Dr F.
Citarella and matches the National Center for Biotechnology Information reference
sequence (NM_000505.3), except for the silent mutation c.nt.1140 T > C (P460P,
mature protein numbering). A sequence coding for a tobacco etch virus (TEV)
protease cleavage site was inserted from the F12 sequence by using PCR with the
Phusion Polymerase (Thermo Fisher Scientific). FXII-W268R was developed
through two-step assembly of three double-stranded DNA segments (annotated as
N, M and C, respectively; Primer sequences in Table 2). Fragment N with the
desired mutation (T859A) was ordered as double-stranded DNA fragments from
Integrated DNA technologies (Coralville, Iowa) and ligated into the pJET1.2/blunt
vector (Thermo Fisher Scientific) according to the manufacturer instructions and
amplified through PCR. Fragments M and C were amplified by PCR from FXII-
WT cDNA in pSM2. First, the N and M segments were digested with XmaI and
subsequently, fused by ligation with T4 ligase (Thermo Fisher Scientific). The fused
product (NM) was amplified via PCR. Hereafter, the NM and C segments were
digested with BsaI and fused together by ligation with T4 ligase. The assembled
cDNA product was ligated into the pJET1.2/blunt vector according to the manu-
facturer’s instructions. Inserts were digested with EcoRI and NotI and ligated into
the EcoRI and NotI-restricted pSM2 vector. All restrictases were purchased from
New England Biolabs (Ipswich, MA). Sequences were verified by Sanger sequen-
cing (Macrogen Europe, Amsterdam, The Netherlands) prior to transfection.
HEK293F (LGC Standards GmbH, Wesel, Germany) cells were transfected using
293fectin (Thermo Fisher Scientific) and cultured in Gibco FreeStyle 293 Expres-
sion Medium (Thermo Fisher Scientific) at a concentration of 1 × 106 cells/ml in
2 ml. Four days after transfection, the cell suspension was centrifuged and 500 × g,
and the supernatant was collected and stored until use at −20 °C. For protein
purification, transfection was repeated in a volume of 1-l cell suspension, and
culture medium was harvested after 1 week. FXII-W268R was purified via a strep-
tag using Strep-Tactin Sepharose beads (IBA-Life Sciences, Goettingen, Germany)
and dialyzed overnight at 4 °C against 4 mM sodium acetate–HCl with 150 mM
NaCl (pH 5.5) using a Spectra/Por dialysis membrane (molecular weight cutoff
3.5 kDa, Spectrum Labs, Rancho Dominguez, California) that was preincubated
with polybrene (Sigma-Aldrich).
Chromogenic assays. Chromogenic substrate H-D-Pro-Phe-Arg-pNA (0.5 mM,
Bachem, Bubendorf, Switzerland) was used to detect FXII activity from recombi-
nant constructs in culture medium. Ninety-six-well Costar plates (Corning, New
York) were blocked with HBS (10 mM HEPES (VWR International, Amsterdam,
The Netherlands), 150 mM NaCl, 1 mM MgSO4, 5 mM KCl, pH= 7.4) containing
0.1% BSA and subsequently, 40 -µl culture medium supernatant containing rFXII
was added followed by 10 µl of substrate. Substrate conversion was immediately
read out at 405 nm at 37 °C. FXII activity in plasma was assessed using the
Chromogenic Assay for Factor XIIa-like Activity (COA0088, CoaChrom Diag-
nostica, Maria Enzersdorf, Austria) as specified by the manufacturer. Absorbance
signals were measured in the VIKTOR X5 (PerkinElmer, Waltham, MA), and
analyzed using GraphPad Prism 7 or Microsoft Excel 2016.
Factor XII concentration ELISA. FXII concentration in plasma was assessed using
the Matched-Pair Antibody Set ELISA of human Factor XII antigen (FXII-EIA,
CoaChrom Diagnostica) as specified by the manufacturer. Absorbance signals were
measured in the VIKTOR X5 (PerkinElmer, Waltham, MA), and analyzed using
GraphPad Prism 7 or Microsoft Excel 2016.
Table 2 Primer sequences for FXII genetic constructs.
N-Frag_For GGAGAATTCGAAAACCTGTATTTTCAGTCTATTCCACC
N-Frag_Rev GCTCCCGGGGTCTGGGACTGAGGCGGGG
M-Frag_For GACCCCGGGAGCCTTGCCGGCGAAGCG
M-Frag_Rev CGTGGTCTCGGAGGGTCGCGCGGCGCCGCTTG
C-Frag_For GACCCTCCGAGACCACGCTCTGCCAGG
C-Frag_Rev CGAGCGGCCGCTCATCAGGAAACGGTGTGCTCCCG
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PK activity (routine lab) and PK ELISA. Prekallikrein activity was assessed by
coagulometric assay in routine measurements at Labor Berlin (13353 Berlin, Ger-
many). Prekallikrein plasma concentration was measured using the Prekallikrein and
Kallikrein Human ELISA (ab171015, Abcam, Cambridge, UK) as specified by the
manufacturer. Absorbance signals were measured in the VIKTOR X5 (PerkinElmer,
Waltham, MA), and analyzed using GraphPad Prism 7.02 or Microsoft Excel 2016.
Enzyme-C1-INH complexes ELISA. Methods on VHH (variable domain heavy-
chain-only antibody) selection, production, and execution for this assay are
described earlier by de Maat25. In brief, VHH 1B12 (5 µg/ml), a monoclonal VHH
directed against complexed C1-INH, was immobilized on 96-well Maxisorp plates
(Corning). Plasma samples were diluted in 10 mM HEPES, 150 mM NaCl, 1 mM
MgSO4, 5 mM KCl, pH= 7.4 (HBS) supplemented with 0.1% (w/v) Tween-20 and
1% (w/v) skimmed milk powder (Sigma-Aldrich) and containing 200 µM Phe-Pro-
Arg-chloromethylketone (PPACK, Haematologic Technologies). For reference,
normal pooled plasma from healthy donors (NPP) activated with DXS (average
molecular weight 500.000, Sigma-Aldrich) for 30 min as well as non-activated NPP
were prepared in HBS containing PPACK and mixed to generate samples con-
taining 0–100% DXS-activated sample. Samples were incubated on the plate for
1 h. Enzyme present in the captured complexes was detected with a biotinylated
polyclonal VHH targeted against the βFXIIA (5 µg/ml, made and biotinylated in-
house47) followed by streptavidin-poly-HRP 1:4000 (M2051, Sanquin Blood Sup-
ply, Amsterdam, The Netherlands) or a polyclonal sheep anti-PK IgG 1:2000
(SAPK-AP, Affinity Biologicals, Hamilton, Canada) followed by HRP-labeled
rabbit anti-sheep IgG 1:4000 (P0163, Dako, Heverlee, Belgium). Finally, 3,3′,5,5′-
tetramethyl-benzidine (TMB, Tebu Bio, Heerhugowaard, The Netherlands) was
added, and substrate conversion was stopped after 5–10 min with H2SO4 (0.3 M),
and absorbance was read out at 450 nm. GraphPad Prism 7.02 software was used to
interpolate the data from the reference range.
Cleaved kininogen activity ELISA. Methods on VHH selection, production, and
execution for this assay are described more detailed by Hofman et al.48. In brief,
patients samples were diluted 64-fold in DPBS (Thermo Fisher Scientific) sup-
plemented with 0.1% (w/v) Tween-20 and 1% (w/v) skimmed milk powder and
containing 200 µM PPACK and 0.5 µg/ml DXS to generate HMWK complexes. For
reference5, min βFXIIa-activated NPP and non-activated NPP samples were pre-
pared and mixed to generate samples with various amounts of cHMWK. After
incubation, cHMWK was detected using a biotinylated monoclonal anti-HMWK
VHH H4 (2 µg/ml, made and biotinylated in-house) and streptavidin-poly-HRP
1:2000. TMB substrate conversion was measured and analyzed as described for the
enzyme-C1-INH complex assays.
Bradykinin ELISA. Bradykinin levels in patient and healthy control plasma were
assessed by ELISA (ADI-900-206, Enzo Life Sciences, Farmingdale, New York) as
described by the manufacturer. Absorption signals were measured in the VIKTOR
X5 and analyzed using GraphPad Prism 7.02 or Microsoft Excel 2016 against
bradykinin standard curves.
IL-1β and IL-8 ELISA. IL-1β/IL-8 secretion was assessed by ELISA (DuoSet,
DY201/DY208-05, R&D Systems, Minneapolis, MN) as specified by the manu-
facturer. For greater precision, ELISAs were carried out at ¼ of the recommended
volumes per well in black NUNC 384-well MaxiSorp plates (Thermo Fisher Sci-
entific) for 4× replicate measurements per original 96-well cell culture plate well. In
addition, instead of TMB, we developed the assay using luminol/H2O2 for
increased sensitivity (Amersham ECL Prime, GE Healthcare, Chicago, IL). Lumi-
nescence signals were measured in the VIKTOR X5 and analyzed using GraphPad
Prism 7.02 or Microsoft Excel 2016 against IL-1β/IL-8 standard curves.
Immunofluorescence cytology/histology. Neutrophils from patient and healthy
donor blood were isolated using the MACSxpress Neutrophil isolation Kit (130-104-
434, Miltenyi Biotec, Bergisch Gladbach, Germany), as specified by the manufacturer.
Isolated neutrophils were washed once with DPBS and ca. In total, 105 cells were
applied to cytospin. Briefly, cells were concentrated to dense spots by centrifugation
onto SuperFrost Plus microscopy slides (Thermo Fisher Scientific) through perforated
cytospin microtubes (Frötek-Kunststofftechnik GmbH, Osterode am Harz, Germany)
and Heraeus perforated cytospin filter cards (Thermo Fisher Scientific) with sub-
sequent fixation by acetone at −20 °C. Cytospins were encircled by PAP pen, blocked
with serum-free protein block (S3022, Dako) for 10min at RT, and incubated with
primary antibody against FXII 1:100 (sc-376770, Santa Cruz Biotechnology, Dallas,
TX) or IL-1β 1:100 (LS-C174781, LSBio, Seattle, WA) in 2% goat normal serum in
TBS for 3 h at RT. After rinsing 3 × 5min with TBS, goat anti-mouse IgG Alexa Fluor
594 conjugate (115-585-062, Jackson Immuno Research, West Grove, Pennsylvania)
was applied 1:200 in 2% goat normal serum in TBS for 30min in the dark, again with
subsequent 3 × 5min rinsing with TBS. In case of double stainings, primary antibody
against MPO (MAB3174, R&D Systems) was incubated together with goat anti-
mouse IgG Alexa Fluor 488 conjugate (115-545-146, Jackson Immuno Research)
1:100 and 1:200, respectively, in 2% goat normal serum in TBS for 1 h in a microtube
in the dark. Free anti-mouse IgG was blocked with 4% final normal mouse serum for
1 h in the dark, and antibody–antibody–dye conjugate was applied to the cytospins
and incubated overnight at 4 °C in the dark. After rinsing 3 × 5min with TBS, slides
were air-dried briefly, mounted using DAPI-Fluoromount G (Thermo Fisher Scien-
tific), and air-dried in the dark for several hours before microscopy. Patient biopsy
was fixed in 4% buffered formalin overnight at RT, and paraffinated using an auto-
mated histokinette (Shandon Citadel 2000 Tissue Processor, Thermo Fisher Scien-
tific). In all, 5-µm skin tissue sections were applied to SuperFrost Plus slides, baked at
60 °C for 1 h and subsequently deparaffinated with 2 × 10min xylene, 2 × 2min 100%
ethanol, 2 × 2min 96% ethanol, 2 min 70% ethanol, and 3min ddH2O. Antigens were
retrieved by incubation at 95 °C in citrate buffer (1.8mM citric acid, 8.6mM Na3
citrate, pH= 6) in a humid atmosphere for 15min. Tissue sections were rinsed in
TBS, encircled with PAP pen, and stained as described above. Samples of liver tissue
(kindly provided by Charité Dpt. of Pathology) served as positive control for FXII.
Sections omitting the primary antibody served as negative controls. Slides were
analyzed by fluorescence microscopy using a Zeiss Axioplan 2 with Axiovision
software 4.8.1. Images of cytospins were further analyzed by ImageJ 1.52a.
Immunohistochemistry. Paraffin sections (5 µm) of a FACAS patient skin sample
and control skin were prepared as explained above, and processed for routine
(hematoxylin/eosin) and immunohistological stainings. We used an immunohis-
tochemistry protocol (streptavidin–biotin labeling) employing primary antibodies
targeting MPO (MAB3174, R&D Systems) 1:400 overnight at 4 °C or CD163
(ab189915, Abcam) 1:400 overnight at 4 °C. After washing 3 × 5min with TBS, REAL
Detection System Alkaline Phosphatase/RED (K5005, Dako) for MPO staining or
labeled polymer-HRP anti-rabbit (K4011, Dako) together with AEC+ high sensitivity
substrate chromogen ready-to-use (K3461, Dako) for CD163 staining were applied
according to the manufacturer’s instructions, and subsequently analyzed by bright-
field microscopy. Samples of tonsil tissue served as positive controls. Sections omitting
the primary antibody served as negative controls.
PBMC stimulation assays. Venous blood from patients and healthy donors was
sampled into heparin tubes. In all, 15 ml of Ficoll-Paque solution (GE Healthcare)
were pipetted into 50-ml Leucosep tubes (Greiner Bio One) and centrifuged at
1000 × g for 1 min. Up to 20 ml of blood sample per tube was added, filled upto
50 ml with DPBS and centrifuged for 10 min at 1000 × g with 33% acceleration and
without breaks. The upper plasma layer was discarded, the PBMC layer was col-
lected and filled into a new 50-ml tube. PBMCs were washed twice by adding ad
50 ml DPBS, centrifugation for 10 min at 350 × g, and resuspension in residual
DPBS. After the washing steps, 10 ml of PBMC medium (RPMI 1640 containing
1% FBS (both from Biochrom, Berlin, Germany), 100 U/ml penicillin, 100 µg/ml
streptomycin (HyClone 100x Pen/Strep, GE Healthcare)) was added, and cells were
counted using trypan blue staining and hematocytometer. PBMC number was
adjusted to 3 × 106/ml, and 100 µl of the suspension were added per well to Falcon
TC treated 96-well plates (Corning). After 2 h incubation at 37 °C and 5% CO2, the
supernatant containing non-monocytes was discarded and to the adherent
monocytes, 100 µl of containing 0.5 ng/ml LPS (E. coli R515, Enzo Life Sciences) or
not was added for NF-κB priming. Monocytes were incubated for 20 h at 37 °C and
5% CO2, supernatant was discarded, and 20 µl per well of PBMC medium was
added. In all, 20 µl of either bradykinin at stated final concentrations or FXII
constructs (with or without stated final concentrations of PPACK) diluted in
PBMC medium were added at a final concentration of 35 ng/µl, followed by
incubation at 37 °C and 5% CO2 for 1 h. Subsequently, 10 µl of 10 mM ATP (Sigma
Aldrich) diluted in PBMC medium were added to a final concentration of 2 mM
for inflammasome activation, followed by another 1 h incubation at 37 °C and 5%
CO2. Supernatants were collected and stored at −20 °C until analysis by ELISA.
Statistical analysis. Sample sizes were limited due to patient availability. The
number of samples (all assessed in duplicates) and experiments are displayed and
listed in the figure legends. The use of statistical tests is indicated in the figure
legends as well.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Source data for figure numbers 2a–e, 3a,c–h, 4b, c, 5a–c, and Supplementary Figs. 1, 2
and 4 are provided as a Source Data file (https://doi.org/10.6084/m9.figshare.11117669)
49. The mass spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE [1] partner repository with the dataset identifier PXD016341.
As the informed consent obtained from FACAS patients does not allow for public
deposition of the sequencing data, the filtered WES sequencing data from patients #2, #5,
and #7 can be communicated upon reasonable request to R.J.P. and S.E. All other
relevant data are contained within the article and its Supplementary Information.
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